TAO Synergies (TAOX) Other Operating Expenses (2019 - 2025)
TAO Synergies' (TAOX) quarterly Other Operating Expenses came in at -$699845.0 in Q4 2025, down 13.17% on a YoY basis from -$806039.5 in Q4 2024, and down 200.0% quarter-over-quarter from $699845.0 in Q2 2025.
Powered by 
Analysis
TAO Synergies (TAOX) Other Operating Expenses (2019 - 2025) Analysis & Trends
TAO Synergies (TAOX) has reported Other Operating Expenses for 4 consecutive years, with -$699845.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Other Operating Expenses fell 13.17% year-over-year to -$699845.0; the trailing twelve-month figure through Jun 2026 stood at -$699845.0 (down 200.0% YoY), and the FY2019 full-year result was $270856.0, changed N/A from the prior year.
- Other Operating Expenses declined to -$699845.0 in Q4 2025 per TAOX's latest filing, from $699845.0 in the prior quarter.
- Across five years, Other Operating Expenses topped out at $699845.0 in Q2 2025 and bottomed at -$699845.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn |
| 10 | TAO Synergies | 30.41 Mn | 30.41 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -699,845.00 |
| Jun 30, 2025 | 699,845.00 |
| Dec 31, 2024 | -618,375.00 |
| Sep 30, 2024 | 618,375.00 |
| Sep 30, 2020 | 387,927.00 |
| Dec 31, 2019 | -3.11 Mn |